Skip to main content
. Author manuscript; available in PMC: 2020 Dec 1.
Published in final edited form as: J Allergy Clin Immunol. 2019 Sep 25;144(6):1566–1574.e6. doi: 10.1016/j.jaci.2019.08.040

Figure 4.

Figure 4.

Evaluation of TATc and TAFI levels in nasal lavage fluids according to clinical background. (A) TATc levels subdivided by comorbidity of asthma in all subjects including control subjects, (B) TAFI levels subdivided by comorbidity of asthma in all subjects including control subjects (▲; non-asthmatic subjects, ♦; asthmatic subjects, n = 15–36), (C) TATc levels subdivided by comorbidity of asthma in CRSwNP subjects, (D) TAFI levels subdivided by comorbidity of asthma in CRSwNP subjects (▼; non-asthmatic subjects, ●; asthmatic subjects, n = 9–12). *P < .05, **P < .01, and ***P < .001.